{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T22:20:14Z","timestamp":1780093214572,"version":"3.54.0"},"reference-count":29,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Robert-Bosch-Stiftung, Stuttgart, Germany"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Oncolytic virotherapy constitutes a promising treatment option for many solid cancers, including peritoneal carcinomatosis (PC), which still represents a terminal stage of many types of tumors. To date, the in vitro efficacy of oncolytic viruses is mostly tested in 2D-cultured tumor cell lines due to the lack of realistic 3D in vitro tumor models. We have investigated the feasibility of virotherapy as a treatment option for PC in a human ex vivo peritoneum co-culture model. Human HT-29 cancer cells stably expressing marker genes GFP and firefly luciferase (GFP\/luc) were cultured on human peritoneum and infected with two prototypic oncolytic viruses (GLV-0b347 and MeV-DsRed). Both viral constructs were able to infect HT-29 cells in patient-derived peritoneum with high tumor specificity. Over time, both GFP signal and luciferase activity decreased substantially, thereby indicating successful virus-induced oncolysis. Furthermore, immunohistochemistry stainings showed specific virotherapeutic infections of HT-29 cells and effective tumor cell lysis in infected co-cultures. Thus, the PC model established here provides a clinically relevant screening platform to evaluate the therapeutic efficacy of virotherapeutic compounds and also to investigate, in an autologous setting, the immunostimulatory potential of oncolytic viruses for PC in a unique human model system superior to standard 2D in vitro models.<\/jats:p>","DOI":"10.3390\/v15020363","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T07:34:41Z","timestamp":1675064081000},"page":"363","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Establishing a New Platform to Investigate the Efficacy of Oncolytic Virotherapy in a Human Ex Vivo Peritoneal Carcinomatosis Model"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5978-3992","authenticated-orcid":false,"given":"Jana","family":"Koch","sequence":"first","affiliation":[{"name":"Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, 70376 Stuttgart, Germany"},{"name":"University of T\u00fcbingen, 72074 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6884-8249","authenticated-orcid":false,"given":"Julia","family":"Beil","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Pneumology, Virotherapy Center T\u00fcbingen (VCT), Medical University Hospital, 72076 T\u00fcbingen, Germany"},{"name":"German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 72076 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Berchtold","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Pneumology, Virotherapy Center T\u00fcbingen (VCT), Medical University Hospital, 72076 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2437-0394","authenticated-orcid":false,"given":"Dina","family":"M\u00f6nch","sequence":"additional","affiliation":[{"name":"Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, 70376 Stuttgart, Germany"},{"name":"University of T\u00fcbingen, 72074 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Maa\u00df","sequence":"additional","affiliation":[{"name":"Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, 70376 Stuttgart, Germany"},{"name":"University of T\u00fcbingen, 72074 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Smirnow","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Pneumology, Virotherapy Center T\u00fcbingen (VCT), Medical University Hospital, 72076 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Schenk","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Pneumology, Virotherapy Center T\u00fcbingen (VCT), Medical University Hospital, 72076 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Carter","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Pneumology, Virotherapy Center T\u00fcbingen (VCT), Medical University Hospital, 72076 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linus D.","family":"Kloker","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Pneumology, Virotherapy Center T\u00fcbingen (VCT), Medical University Hospital, 72076 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Leibold","sequence":"additional","affiliation":[{"name":"Department of General and Visceral Surgery, Robert Bosch Hospital, 70376 Stuttgart, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Renner","sequence":"additional","affiliation":[{"name":"Department of General and Visceral Surgery, Robert Bosch Hospital, 70376 Stuttgart, Germany"},{"name":"University Medical Centre Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-H.","family":"Dahlke","sequence":"additional","affiliation":[{"name":"Department of General and Visceral Surgery, Robert Bosch Hospital, 70376 Stuttgart, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich M.","family":"Lauer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Pneumology, Virotherapy Center T\u00fcbingen (VCT), Medical University Hospital, 72076 T\u00fcbingen, Germany"},{"name":"German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 72076 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1463-1318.2007.01345.x","article-title":"Biology of the peritoneum in normal homeostasis and after surgical trauma","volume":"9","author":"Jeekel","year":"2007","journal-title":"Color. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00018-017-2663-1","article-title":"The peritoneal \u201csoil\u201d for a cancerous \u201cseed\u201d: A comprehensive review of the pathogenesis of intraperitoneal cancer metastases","volume":"75","author":"Uruski","year":"2018","journal-title":"Cell Mol. Life Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ncponc0736","article-title":"Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress","volume":"4","author":"Liu","year":"2007","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: A new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/OV.S165479","article-title":"Three-dimensional tumor cell cultures employed in virotherapy research","volume":"7","author":"Kloker","year":"2018","journal-title":"Oncolytic Virother"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1515\/pp-2021-0128","article-title":"A human ex vivo coculture model to investigate peritoneal metastasis and innovative treatment options","volume":"6","author":"Koch","year":"2021","journal-title":"Pleura Peritoneum"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Koch, J., M\u00f6nch, D., Maass, A., Mangold, A., Guzvic, M., M\u00fcrdter, T., Leibold, T., Dahlke, M.H., and Renner, P. (2022). Pharmacologic Targeting of MMP2\/9 Decreases Peritoneal Metastasis Formation of Colorectal Cancer in a Human Ex Vivo Peritoneum Culture Model. Cancers, 14.","DOI":"10.3390\/cancers14153760"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1080\/21645515.2020.1840887","article-title":"Vaccinia virus-based vector against infectious diseases and tumors","volume":"17","author":"Zhang","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13578-021-00610-8","article-title":"Why do poxviruses still matter?","volume":"11","author":"Yang","year":"2021","journal-title":"Cell Biosci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"826302","DOI":"10.3389\/fmolb.2022.826302","article-title":"A Three-Dimensional Organoid Model of Primary Breast Cancer to Investigate the Effects of Oncolytic Virotherapy","volume":"9","author":"Carter","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"ref_11","first-page":"554","article-title":"A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma","volume":"24","author":"Lange","year":"2013","journal-title":"Hum. Gene"},{"key":"ref_12","first-page":"1391","article-title":"An ex vivo model using human peritoneum to explore mesh-tissue integration","volume":"6","author":"Falk","year":"2017","journal-title":"Biol. Open"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","article-title":"New colorimetric cytotoxicity assay for anticancer-drug screening","volume":"82","author":"Skehan","year":"1990","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1099\/vir.0.069591-0","article-title":"A role for vaccinia virus protein C16 in reprogramming cellular energy metabolism","volume":"96","author":"Mazzon","year":"2015","journal-title":"J. Gen. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41416-019-0530-6","article-title":"Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma","volume":"121","author":"Chesney","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3892\/ijo.2013.1914","article-title":"Primary resistance phenomena to oncolytic measles vaccine viruses","volume":"43","author":"Noll","year":"2013","journal-title":"Int. J. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Berchtold, S., Beil, J., Raff, C., Smirnow, I., Schell, M., D\u2019Alvise, J., Gross, S., and Lauer, U.M. (2020). Assessing and Overcoming Resistance Phenomena against a Genetically Modified Vaccinia Virus in Selected Cancer Cell Lines. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207618"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.2217\/fon-2022-0440","article-title":"Oncolytic viruses: Challenges and considerations in an evolving clinical landscape","volume":"18","author":"Lauer","year":"2022","journal-title":"Future Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ji, Q., Wu, Y., Albers, A., Fang, M., and Qian, X. (2022). Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14091811"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Nettelbeck, D.M., Leber, M.F., Altomonte, J., Angelova, A., Beil, J., Berchtold, S., Delic, M., Eberle, J., Ehrhardt, A., and Engeland, C.E. (2021). Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies. Viruses, 13.","DOI":"10.3390\/v13081420"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/1078-0432.CCR-18-0244","article-title":"Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis","volume":"24","author":"Lauer","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Tate, S.J., Van de Sande, L., Ceelen, W.P., Torkington, J., and Parker, A.L. (2021). The Feasibility of Pressurised Intraperitoneal Aerosolised Virotherapy (PIPAV) to Administer Oncolytic Adenoviruses. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13122043"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.omto.2022.03.003","article-title":"Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response","volume":"25","author":"Zhang","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ygyno.2021.10.069","article-title":"A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer","volume":"163","author":"Manyam","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_25","first-page":"A9","article-title":"Oncolytic vaccinia (OLVI-VEC) primed immunochemotherapy in platinum-resistant\/refractory ovarian cancer","volume":"30","author":"Holloway","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1158\/0008-5472.CAN-14-2533","article-title":"Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer","volume":"75","author":"Galanis","year":"2015","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ygyno.2017.07.135","article-title":"Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin(R)) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology\/Gynecologic Oncology Group study","volume":"146","author":"Cohn","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/sj.cgt.7700510","article-title":"Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer","volume":"9","author":"Bennett","year":"2002","journal-title":"Cancer Gene"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.omto.2020.06.021","article-title":"Boosting Replication and Penetration of Oncolytic Adenovirus by Paclitaxel Eradicate Peritoneal Metastasis of Gastric Cancer","volume":"18","author":"Ishikawa","year":"2020","journal-title":"Mol. Ther. Oncolytics"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/2\/363\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:16:55Z","timestamp":1760120215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/2\/363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["v15020363"],"URL":"https:\/\/doi.org\/10.3390\/v15020363","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,27]]}}}